New data could widen use of AstraZeneca, Amgen immune disease drug
BioPharma Dive
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug s third approved indication and unlock what s viewed as a blockbuster opportunity.
pharminent
August 27, 2026 (Last updated: September 1, 2026)
BioPharma Dive
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug s third approved indication and unlock what s viewed as a blockbuster opportunity.
